Enhancing the Efficacy of Stem Cell Therapy with Glycosaminoglycans.
Download
Date
2020-01-14Source Title
Stem Cell ReportsPublisher
Elsevier BVAffiliation
Medicine Dentistry & Health SciencesMetadata
Show full item recordDocument Type
Journal ArticleCitations
Ling, L., Ren, X., Cao, X., Hassan, A. B. M., Mah, S., Sathiyanathan, P., Smith, R. A. A., Tan, C. L. L., Eio, M., Samsonraj, R. M., van Wijnen, A. J., Raghunath, M., Nurcombe, V., Hui, J. H. & Cool, S. M. (2020). Enhancing the Efficacy of Stem Cell Therapy with Glycosaminoglycans.. Stem Cell Reports, 14 (1), pp.105-121. https://doi.org/10.1016/j.stemcr.2019.12.003.Access Status
Open AccessOpen Access at PMC
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962655Abstract
Human mesenchymal stem cell (hMSC) therapy offers significant potential for osteochondral regeneration. Such applications require their ex vivo expansion in media frequently supplemented with fibroblast growth factor 2 (FGF2). Particular heparan sulfate (HS) fractions stabilize FGF2-FGF receptor complexes. We show that an FGF2-binding HS variant (HS8) accelerates the expansion of freshly isolated bone marrow hMSCs without compromising their naivety. Importantly, the repair of osteochondral defects in both rats and pigs is improved after treatment with HS8-supplemented hMSCs (MSCHS8), when assessed histologically, biomechanically, or by MRI. Thus, supplementing hMSC culture media with an HS variant that targets endogenously produced FGF2 allows the elimination of exogenous growth factors that may adversely affect their therapeutic potency.
Export Reference in RIS Format